Pharmaceuticals
Aspen Pharma in midst of cancer drug price-gouging row
17 Apr 2017
Aspen Pharmacare allegedly “plotted to destroy supplies of life-saving cancer medicines” to drive up prices in Europe, after the firm bought the rights to five cancer medicines from GlaxoSmithKline and sought to impose rises of up to 4,000 per cent
